article thumbnail

A Public Health Wake-Up Call: Reading Between the Lines in IQVIA’s 2023 Use of Medicines Report

Health Populi

Reviewing the annual 2023 report from the IQVIA Institute for Human Data Science discussing The Use of Medicines in the U.S. It’s a volume speaking volumes on the current picture of prescribed meds, spending and revenues, health care utilization trends, and a forecast looking out to 2027.

article thumbnail

Wellness in 2023 Is About Connections, Mental Health and Science – Global Wellness Summit’s 2023 Trends

Health Populi

Consumers’ wellness life-flows and demands in 2023 will go well beyond exercise resolutions, eating more greens, and intermittent fasting as a foodstyle. The 2023 Edelman Trust Barometer found that scientists are the most-trusted institutional leader this year, ranked above all other leader types.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bonus Features – May 7, 2023 – Less than 1% of all medical claims include an ICD-10 Z code, 78% of consumers say virtual health is important when considering health plans, and more

Healthcare IT Today

After receiving more than 38,000 public comments, the Drug Enforcement Administration is extending the telemedicine flexibilities for prescribing controlled medications beyond the end of the public health emergency on May 11. The silver lining: Healthcare is the leading sector, though most funds are going to biotech.

RCM 79
article thumbnail

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Digital Health Global

Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. 2 Digital health is a large (+$900bn by 2032) and growing (13.6%